Stock Fundamentals

Company Information

Company Name
Harmony Biosciences Holdings
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US4131971040
CIK: 0001802665
CUSIP: 413197104
Currency: USD
Full Time Employees: 293
Phone: 484 539 9800
Fiscal Year End: December
IPO Date: Aug 19, 2020
Description:

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Address:

630 West Germantown Pike, Plymouth Meeting, PA, United States, 19462

Directors & Officers

Name Title Year Born
Mr. Jeffrey S. Aronin Founder & Non-Executive Chairman 1968
Dr. Jeffrey M. Dayno M.D. President, CEO & Director 1957
Mr. Peter Anastasiou Chief Operating Officer 1970
Dr. Kumar Budur M.D., M.S. Executive VP and Chief Medical & Scientific Officer 1971
Mr. Andrew Serafin J.D., M.B.A. Executive VP & Chief Strategy Officer 1975
Mr. Adam Zaeske Executive VP & Chief Commercial Officer 1973
Mr. Glenn M. Reicin M.B.A. Chief Financial Officer 1965
Brennan Doyle VP & Head of Investor Relations NA
Mr. Christian Ulrich J.D. Executive VP, General Counsel & Corporate Secretary NA
Ms. Tricia Glover Chief Compliance Officer NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Jan 26, 2026 Sandip Kapadia N/A Sale 3.75K $37.15 $139.16K
Jan 15, 2026 Sandip Kapadia N/A Sale 20.96K $35.92 $752.92K
Dec 12, 2025 Jeffrey M Dayno N/A Sale 25.93K $40.11 $1.04M

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 7.07M Mar 31, 2026 12.22% $0.00 -0.26%
Vanguard Group Inc 4.81M Dec 31, 2025 8.32% $0.00 -5.57%
FMR Inc 3.16M Mar 31, 2026 5.46% $0.00 1.44%
American Century Companies Inc 2.11M Mar 31, 2026 3.64% $0.03 14.31%
Dimensional Fund Advisors, Inc. 2.08M Mar 31, 2026 3.59% $0.01 13.43%
LSV Asset Management 2.03M Mar 31, 2026 3.50% $0.12 22.21%
SG Americas Securities, LLC 2.02M Mar 31, 2026 3.49% $0.06 109.86%
State Street Corp 1.78M Mar 31, 2026 3.08% $0.00 7.37%
Armistice Capital, LLC 1.62M Mar 31, 2026 2.81% $0.81 224.80%
Arrowstreet Capital Limited Partnership 1.38M Mar 31, 2026 2.39% $0.02 -7.34%
Geode Capital Management, LLC 1.32M Mar 31, 2026 2.29% $0.00 4.10%
The Goldman Sachs Group Inc 1.24M Mar 31, 2026 2.14% $0.00 117.65%
Renaissance Technologies Corp 1.08M Mar 31, 2026 1.86% $0.05 0.64%
Morgan Stanley - Brokerage Accounts 1.03M Mar 31, 2026 1.78% $0.00 26.12%
Millennium Management LLC 954.36K Mar 31, 2026 1.65% $0.01 311.90%
JPMorgan Chase & Co 823.51K Mar 31, 2026 1.42% $0.00 313.08%
Two Sigma Investments LLC 733.44K Mar 31, 2026 1.27% $0.02 254.40%
AQR Capital Management LLC 716.25K Mar 31, 2026 1.24% $0.01 -12.00%
Amvescap Plc. 628.25K Mar 31, 2026 1.09% $0.00 39.36%
Trexquant Investment LP 594.85K Mar 31, 2026 1.03% $0.12 98.68%

Shares Statistics

Shares Outstanding: 57.89M
Shares Float: 51.73M
% Insiders: 1,169.20%
% Institutions: 10,339.80%
Short % Float: 15.30%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 iShares Core S&P Small-Cap ETF 2.42M 4.19% ▲ 0.02% Apr 30, 2026
2 HBM Healthcare Investments AG Ord 2.15M 3.71% ▲ 0.00% Mar 31, 2026
3 Avantis US Small Cap Value ETF 1.90M 3.29% ▲ 0.00% Apr 30, 2026
4 Vanguard Total Stock Mkt Idx Inv 1.57M 2.71% ▲ 0.00% Apr 30, 2026
5 Fidelity Growth Compy Commingled Pl S 1.47M 2.54% ▲ 0.06% Mar 31, 2026
6 Vanguard Small Cap Index 1.13M 1.96% ▲ 0.02% Apr 30, 2026
7 iShares Russell 2000 ETF 1.03M 1.78% ▲ 0.85% Apr 30, 2026
8 Fidelity Growth Company Fund 1.01M 1.74% ▲ 0.00% Mar 31, 2026
9 BlackRock Global Equity Mkt Netrl Instl 710.15K 1.23% ▼ 2.31% Apr 30, 2026
10 Vanguard Small Cap Growth Index Inv 633.54K 1.09% ▼ 0.08% Apr 30, 2026

Valuation Metrics

Enterprise Value: $1.36B
Trailing P/E: 12.46
Forward P/E: 10.08

Financial Highlights

Market Cap: $1.79B
EBITDA: $214.85M
P/E Ratio: $12.46
Book Value: $15.73
Earnings/Share: $2.48
Profit Margin: 16.20%
Operating Margin: 17.31%
ROA (TTM): 10.18%
ROE (TTM): 17.86%
Revenue (TTM): $899.11M
Revenue/Share (TTM): $15.60
Earnings Growth (YOY): -29.50%
Revenue Growth (YOY): 16.60%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 3.60x 0.26x 0.32x 14.23x 0.90x
2024-12-31 3.31x 0.27x 0.34x 10.91x 0.77x
2023-12-31 2.75x 0.41x 0.42x 8.08x 0.87x
2022-12-31 5.07x 0.48x 0.40x 6.39x 1.30x
2021-12-31 5.29x 1.04x 0.57x 3.62x 2.40x
2020-12-31 1.95x 2.00x 0.77x 0.60x 128.39x
2019-12-31 1.58x -8.45x 1.11x -24.03x -0.69x
2018-12-31 11.99x 0.00x 0.09x N/A 0.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about HRMY.US!